4.7 Article

Validation of the Pathogenic Effect of IGHMBP2 Gene Mutations Based on Yeast S. cerevisiae Model

Journal

Publisher

MDPI
DOI: 10.3390/ijms23179913

Keywords

SMARD1; IGHMBP2 gene; missense mutations; disease model; yeast Saccharomyces cerevisiae; CMT2S

Funding

  1. National Science Centre Poland [2020/04/X/NZ2/00377]

Ask authors/readers for more resources

In this study, a simple yeast model was developed to evaluate the significance of IGHMBP2 gene mutations in the development of SMARD1. The results showed that the model can distinguish between pathogenic and non-pathogenic mutations, providing important insights for clinical diagnosis.
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a heritable neurodegenerative disease characterized by rapid respiratory failure within the first months of life and progressive muscle weakness and wasting. Although the causative gene, IGHMBP2, is well defined, information on IGHMBP2 mutations is not always sufficient to diagnose particular patients, as the gene is highly polymorphic and the pathogenicity of many gene variants is unknown. In this study, we generated a simple yeast model to establish the significance of IGHMBP2 variants for disease development, especially those that are missense mutations. We have shown that cDNA of the human gene encodes protein which is functional in yeast cells and different pathogenic mutations affect this functionality. Furthermore, there is a correlation between the phenotype estimated in in vitro studies and our results, indicating that our model may be used to quickly and simply distinguish between pathogenic and non-pathogenic mutations identified in IGHMBP2 in patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available